Serum KL-6, SP-D and MMP-2 as diagnostic biomarkers in asbestosis and silicosis Source: International Congress 2017 – Silicosis has not gone away Year: 2017
Biomarkers of Sarcoidosis: a comparative study of serum chitotriosidase, ACE, lysozyme and KL-6 Source: International Congress 2019 – Granulomatous disorders: pathogenesis, epidemiology and clinical issues Year: 2019
Human napsin a is a useful serum marker of interstitial lung disease, compared to KL-6, and surfactant protein-D Source: Annual Congress 2009 - Bronchoalveolar lavage and phenotyping in diffuse parenchymal lung disease Year: 2009
YKL-40 and KL-6 in serum and sputum samples of patients diagnosed with hypersensitivity pneumonitis. Source: International Congress 2019 – Environment, work and respiratory health in occupational and environmental lung diseases Year: 2019
Serum and BALF levels of YKL-40 in patients with alveolar proteinosis Source: Annual Congress 2010 - Biomarkers in diffuse parenchymal lung disease Year: 2010
Serum concentrations of KL-6 in patients with IPF and lung cancer and serial measurements of KL-6 in IPF patients treated with antifibrotic therapy Source: Virtual Congress 2021 – Biomarkers and e-health in idiopathic interstitial pneumonia Year: 2021
High serum levels of YKL-40 in IPF Source: Annual Congress 2008 - Novel mechanisms and targets of molecular pulmonary pathology Year: 2008
Serum KL-6 as a marker of disease progression in SSc-ILD Source: International Congress 2018 – CTD-ILD and hypersensitivity pneumonitis: from the bench to the bedside Year: 2018
High level of serum SP-D with normal range of KL-6 predicts a good prognosis of patients with fibrotic changes on HRCT Source: Annual Congress 2010 - Biomarkers in diffuse parenchymal lung disease Year: 2010
KL-6 serum levels in adult cystic fibrosis patients Source: Annual Congress 2011 - Cystic fibrosis: clinical and laboratory studies Year: 2011
Study of angiotensin-converting enzyme, serum amyloid A, soluble interleukin-2 receptor, lysozyme and KL-6 in serum as diagnostic markers in pulmonary sarcoidosis Source: Annual Congress 2007 - Sarcoidosis: various aspects Year: 2007
Serum neopterin and IL-6 as biomarkers in patients with COPD. Source: International Congress 2017 – Novel molecular and genetic targets in COPD Year: 2017
Usefulness of serum procalcitonin in lung cancer patients with elevated serum C-reactive protein level Source: Annual Congress 2011 - Instructive clinical aspects of lung cancer Year: 2011
Elevated levels of BALF galectin-9 in patients with interstitial pneumonia Source: Annual Congress 2009 - Airways remodelling Year: 2009
KL-6 as a marker of alveolar inflammation in patients with ARDS Source: Eur Respir J 2006; 28: Suppl. 50, 635s Year: 2006
CCL20 level in bronchoalveolar lavage fluid is correlated with the levels of serum indications in patients with pulmonary sarcoidosis Source: Annual Congress 2010 - Usefulness of bronchoalveolar lavage in diffuse parenchymal lung disease Year: 2010
Serum markers of IPF Source: Research Seminar 2004 - Genotyping and Phenotyping of Diffuse Parenchymal Lung Diseases Year: 2004
Elevated serum inflammatory markers in patients with stable COPD Source: Annual Congress 2009 - Respiratory mechanics, tissue and cell dysfunction in pulmonary disease Year: 2009
Change in serum surfactant protein (SP)-A, SP-D and KL-6 predict the therapeutic effect of antifibrotic drugs in IPF. Source: International Congress 2019 – Biomarkers of idiopathic interstitial pneumonia Year: 2019
PP102 – A serum biomarker reflecting human neutrophil elastase degraded calprotectin is elevated in COPD and IPF Source: ERS Lung Science Conference 2021 Year: 2021